Chemotherapy of advanced non-small cell lung cancer

Annals of Oncology

Volumn 10, Issue SUPPL. 6, 1999, Pages

  Jassem, Jacck ^a  

^a MEDICAL UNIVERSITY OF GDANSK   (Poland)

Author keywords

Chemotherapy; Non small cell lung cancer

Indexed keywords

CARBOPLATIN; CISPLATIN; DOCETAXEL; ETOPOSIDE; GEMCITABINE; IFOSFAMIDE; IRINOTECAN; MITOMYCIN; NAVELBINE; PACLITAXEL; TOPOTECAN; VINDESINE;

CANCER CHEMOTHERAPY; CANCER SURVIVAL; CONFERENCE PAPER; COST EFFECTIVENESS ANALYSIS; DRUG COST; HEALTH CARE COST; HEALTH ECONOMICS; HOSPITALIZATION; LUNG NON SMALL CELL CANCER; META ANALYSIS; PATIENT SELECTION; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; TREATMENT OUTCOME;

EID: 0033374718     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/10.suppl_6.S77     Document Type: Conference Paper

References (73)

1. Parker SL, Tong T, Bolden S et al. Cancer Statistics, 1997. CA Cancer J Clin 1997; 47: 5-27.
2. Ries LAG, Hankey BF, Miller BA et al. National Cancer Institute, Cancer Statistics Review. Bethesda, MD, National Institute of Health, 1991, pp 1973-88.
3. Ihde DC, Minna JD. Non-small cell lung cancer. I. Biology, diagnosis and therapy. Curr Probl Cancer 1991; 15: 61-104.
4. Feld R, Rubinstein LV, Weisenberger T. Sites of recurrence in resected stage I non-small cell lung cancer: a guide for future studies. J Clin Oncol 1984; 2: 1352-8.
5. Perez CA, Pajak TF, Rubin P et al. Long-term observations of the patterns of failure in patients with unresectable non-oat cell carcinoma of the lung treated with definitive radiotherapy: report by the Radiation Therapy Oncology Group. Cancer 1987; 59: 1874-81.
6. Finkelstein DM, Ettinger DS, Ruckdeschel JC. Long-term survivors in metastatic non-small cell lung cancer: an Eastern Cooperative Group study. J Clin Oncol 1986; 4: 702-9.
7. Van Zandwijk N, Giaccone G. Treatment of metastatic non-small cell lung cancer. Curr Opin Oncol 1996; 8: 120-5.
8. Ihde DC. Chemotherapy of lung cancer. N Engl J Med 1992; 327: 14-1441.
9. Slevin ML, Stubbs L, Plant HJ et al. Attitudes to chemotherapy: comparing views of patients with cancer with those of doctors, nurses, and general public. Br Med. J 1990; 300: 1458-60.
10. Raby B, Pater J, Mackillop WJ. A survey of Canadian physician's beliefs about the use of radiation and chemotherapy in non-small cell lung cancer. Proc Am Soc Clin Oncol 1994; 13: 327 (abstract).
11. Bonomi P. Non-small cell lung cancer chemotherapy. In: Pass HL, Mitchell JB, Johnson DH, Turrisi AT (eds.). Lung cancer: principles and practice. Lippincott-Raven, Philadelphia, New York, 1996; 811-23.
12. Grilli R, Oxman AD, Julian JA. Chemotherapy for advanced non-small-cell lung cancer: How much benefit is enough? J Clin Oncol 1993; 11: 1866-72.
13. Souquet PJ, Chauvin E, Boissel JP et al. polychemotherapy in advanced non small cell lung cancer: A meta-analysis. Lancet 1993; 342: 19-21.
14. Marino P, Pampallona S, Preatoni A et al. Chemotherapy vs supportive care in advanced non-small cell lung cancer. Results of a meta-analysis of the literature. Chest 1994; 106: 861-5.
15. Non-small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised trials. Br Med. J 1995; 311: 899-909.
16. American Society of Clinical Oncology. Clinical practice guidelines for the treatment of unresectable non-small-cell lung cancer. J Clin Oncol 1997; 15: 2996-3018.
17. O'Conell JP, Kris MG, Gralla RJ et al. Frequency and prognostic importance of pretreatment clinical characteristics in patients with advanced non-small cell lung cancer treated with combination chemotherapy. J Clin Oncol 1986; 4: 1604-14.
18. Albain KS, Crowley JJ, LeBlanc M et al. Survival determinants in extensive-stage non small cell lung cancer: the Southwest Oncology Group experience. J Clin Oncol 1991; 9: 1618-26.
19. Paesmans M, Sculier JP, Libert P et al. Prognostic factors for survival in advanced non-small cell lung cancer: Univariate and multivariate analysis including recursive partitioning and amalgamation algorithms in 1,052 patients. J Clin Oncol 1995; 13: 1221-30.
20. De Wys WD, Begg C, Lavin PT et al. Prognostic effect of weight loss prior to chemotherapy in cancer patients. Am J Med. 1980; 69: 491-7.
21. Shaw GL, Gazdar AF, Phelps R et al. Individualized chemotherapy for patients with non-small cell lung cancer determined by prospective identification of neuroendocrine markers and in vitro drug sensitivity testing. Cancer Res 1993; 53: 5181-87.
22. Van Zandwijk N, Jassem E, Bonfrer JMG et al. Serum neuron specific enolase and lactate dehydrogenase as predictors to chemotherapy and survival in non-small cell lung cancer. Sem Oncol 1992; 19 (suppl. 2): 37-43.
23. Jassem E, Jassem J. Clinical relevance of genetic alterations in lung cancer. In: Mackiewicz A, Seghal PB (eds.): Molecular aspects of cancer and its therapy. Birkhauscr Verlag, Bassel 1998, 45-57.
24. Ruckdeschel JC, Finkelstein DM, Ettinger DS et al. A randomized trial of the four most active regimens for metastatic non-small cell lung cancer. J Clin Oncol 1986; 4: 14-22.
25. Ihde DC, Minna JD. Non-small cell lung cancer. II. Treatment. Curr Probl Cancer 1991; 15: 109-54.
26. Bakowski MT, Crouch JD. Chemotherapy of non-small cell lung cancer: a reappraisal and a look to the future. Cancer Treat Rev 1983; 10: 159-72.
27. Klastersky J, Sculier JP, Lacroix H et al. A randomized study comparing cisplatin or carboplatin with etoposide in patients with advanced non-small cell lung cancer: European Organization for Research and Treatment of Cancer - protocol 07861. J Clin Oncol 1990; 8: 1556-62.
28. Sculier JP, Klastersky J, Giner V et al. Phase 11 randomized trial comparing high-dose cisplatin with moderate-dose cisplatin and carboplatin in patients with advanced non-small cell lung cancer. J Clin Oncol 1994; 12: 353-59.
29. Bonomi PD, Finkelstein DM, Ruckdeschel JC et al. Combination chemotherapy versus single agents followed by combination chemotherapy in stage IV non-small cell lung cancer: a study of the Eastern Cooperative Oncology Group. J Clin Oncol 1989; 7: 1602-13.
30. Klastersky J, Sculier JP, Bureau G et al. Cisplatin versus cisplatin plus etoposide in the treatment of advanced non-small cell lung cancer. J Clin Oncol 1989; 7: 1087-92.
31. Kawahara M, Furuse K, Nagohesa K et al. A randomized study of cisplatin versus cisplatin plus vindesine for non-small cell lung cancer. Cancer 1991; 68: 714-9.
32. Gandara DR, Crowley J, Livingston RB et al. Evaluation of cisplatin intensity in metastatic non-small cell lung cancer: a phase III study of the Southwest Oncology Group. J Clin Oncol 1993; 11: 873-8.
33. Gatzemeier U, von Pawel J, Gottfried M et al. Phase III comparative study of high-dose cisplatin versus a combination of paclitaxel and cisplatin in patients with advanced non-small cell lung cancer. Proc Am Soc Clin Oncol 1998; 17: 454a (abstract).
34. Sandler A, Nemunaitis J, Dehnam C et al. Phase III study of cisplatin with or without gemcitabine in patients with advanced nonsmall cell lung cancer. Proc Am Soc Clin Oncol 1998; 17: 454a (abstract).
35. Wozniak AJ, Crowley JJ, Balcerzak SP et al. Randomized phase III trial of cisplatin (CDDP) vs. CDDP plus navelbine (NVB) in treatment of advanced non-small cell lung cancer(NSCLC): an update of a Southwest Oncology Group Study (SWOG-9308). Proc Am Soc Clin Oncol 1998; 17: 45-3a (abstract).
36. Goldie JH, Coldman AJ, Gudauskas GA. Rationale for the use of alternating non-cross resistant chemotherapy. Cancer Treat Rep 1982; 66: 439-49.
37. Miller TP, Chen TT, Cottman CA et al. Effect of alternating combination chemotherapy on survival of ambulatory patients with metastatic large-cell and adenocarcinoma of the lung: a Southwest Oncology Group study. J Clin Oncol 1986; 4: 502-8.
38. Weiek JK, Crowley J, Natale RB et al. A randomized trial of five cisplatin-containing treatments in patients with non-small cell lung cancer: a Southwest Oncology Group study. J Clin Oncol 1991; 9: 1157-62.
39. Cormier Y, Bergeron D, La Forge J et al. Benefits of polychemotherapy in advanced non-small cell bronchogenic carcinoma. Cancer 1982; 50: 845-9.
40. Fukuoka M., Masuda N, Furuse K et al. A randomized trial in inoperable non-small cell lung cancer: vindesine and cisplatin versus mitomycinvindesine and cisplatin alternatively with vindesine and mytomycin. J Clin Oncol 1991; 9: 606-13.
41. Klastersky J, Sculier JP, Ravez P. et al. A randomized study comparing a high and a standard dose of cisplatin in combination with etoposide in the treatment of advanced non-small cell lung cancer. J Clin Oncol 1986; 4: 1780-6.
42. Shinkai T, Sajijo N, Eguchi K et al. Cisplatin and vindesine combination chemotherapy for non-small cell lung cancer: A randomized trial comparing two dosages of cisplatin. Jpn J Cancer Res 1986; 77: 782-9.
43. Davis S, Rambotti P, Park YK. Combination cyclophosphamide, doxorubicin, and cisplatin (CAP) chemotherapy for extensive non-small cell lung carcinomas of the lung. Cancer Treat Rep 1981; 65: 955-8.
44. Sculier JP, Paesmans M, Thiriaux J et al. Phase III randomized trial comparing cisplatin and carboplatin with and without ifosfamide in patients with advanced non-small cell lung cancer. J Clin Oncol 1998; 16: 1388-96.
45. Kosmidis P, Mylonakis N, Skarlos DV et al. A comparative study of cisplatin and vinblastine versus ifosfamide, cisplatin and vinblastine in non-operable non-small cell lung cancer. Ann Oncol 1994; 5: 159-62.
46. Buccheri G, Ferrigno D, Curcio A et al. Continuation of chemotherapy versus supportive care alone in patients with inoperable non-small cell lung cancer and stable disease after two or three cycles of MACC. Results of a randomized prospective study. Cancer 1989; 63: 428-32.
47. Smith IE, O'Brien MER, Norton A. Duration of chemotherapy for advanced non-small cell lung cancer (NSCLC): a phase III randomised trial of 3 versus 6 courses of mitomycin C, vinblastine, cisplatin (MVP). Proc Am Soc Clin Oncol 1998; 17: 457a (abstract).
48. Rajkumar SV, Adjci AA. A review of the pharmacology and clinical activity of new chemotherapeutic agents in lung cancer. Cancer Treat Rev 1998; 24: 35-53.
49. Bunn PA, Kelly K. New chemotherapeutic agents prolong survival and improve quality of life in non-small cell lung cancer: a review of the literature and future directions. Clin Cancer Res 1998; 5: 1087-1100.
50. Thatcher N, Niven RM, Anderson H. Aggressive vs. nonaggressive therapy in metastatic NSCLC. Chest 1996; 109 (suppl.): 87S-92S.
51. Le Chevalier T, Brisgard D, Douillard JY et al. Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small cell lung cancer: Results of European multicenter trial including 612 patients. J Clin Oncol 1994; 12: 360-7.
52. Bonomi P, Kim K, Chang A et al. Phase III trial comparing etoposide (H) cisplatin (P) versus Taxol (T) with cisplatin-G-CSF versus Taxolcisplatin in advanced non-small cell lung cancer. An Eastern Cooperative Oncology Group (ECOG) trial.Proc Am Soc Clin Oncol 1996; 15: 382a (abstract).
53. Cardenal F, Rosell R, Anton A et al. Gemcitabine + cisplatin in advanced non-small cell lung cancer patients: preliminary randomized phase III results. Proc Am Soc Clin Oncol 1997; 16: 458a (abstract).
54. Crino L, Conte P., De Marinis F et al. A randomised trial of gemcitabine cisplatin (GP) versus mitomycin, ifosfamide and cisplatin (MIC) in advanced non-small cell lung cancer. A multicenter phase MI study. Proc Am Soc Clin Oncol 1998; 17: 455a (abstract).
55. Belani CP, Natal RB, Lee JS et al. Randomized phase III trial comparing cisplatin/etoposide versus carboplatin/paclitaxel in advanced and metastatic non-small cell lung cancer. Proc Am Soc Clin Oncol 1998; 17: 455a (abstract).
56. Giaccone G, Splinter T, Postmus P et al. Paclitaxel-cisplatin versus teniposide-cisplatin in advanced non-small cell lung cancer. Proc Am Soc Clin Oncol 1996; 15: 373a (abstract).
57. Fosella FV, Lee JS, Shin DM et al. Phase II study of docetaxel for advanced or metastatic platinum-refractory non-small cell lung cancer. J Clin Oncol 1995; 13: 645-51.
58. Gridelli C, Airoma G, Incoronato P et al. Mitomycin C plus vindesine or cisplatin plus epirubicin in previously treated patients with symptomatic advanced non-small cell lung cancer. Cancer Chemother Pharmacol 1992; 30: 212-4.
59. Pronzato P, Landucci M, Vaira F et al. Failure of vinorelbine to produce responses in pretreated non-small cell lung cancer. Anticancer Res 1994; 14: 1413-5.
60. Crino L, Mosconi AM, Scagliotti G et al. Salvage chemotherapy with gemcitabine in pretreated, advanced non-small cell lung cancer. Proc Am Soc Clin Oncol 1997; 16: 446a (abstract).
61. Rapp E, Pater JL, Willan A et al. Chemotherapy can prolong survival in patients with advanced non-small cell lung cancer report of a Canadian multicenter randomized trial. J Clin Oncol 1988; 6: 633-41.
62. Outcomes Working Group, Health Services Research Committee, American Society of Clinical Oncology. Outcomes of cancer treatment for technology assessment and cancer treatment guidelines. J Clin Oncol 1996; 14: 671-9.
63. Ellis PA, Smith IE, Hardy JR et al. Symptom relief with MVP(mitomycin C, vinblastine and cisplatin) chemotherapy in advanced non-small cell lung cancer. Br J Cancer 1995; 71: 366-70.
64. Fernandez C, Rosell R, Abad-Esteve A. Quality of life during chemotherapy in non-small cell lung cancer patients. Acta Oncol 1989; 28: 129-33.
65. Osoba D, Rusthoven JJ, Turnbull KA et al. Combination chemotherapy with bleomycin, etoposide and cisplatin in metastatic non-small cell lung cancer. J Clin Oncol 1985; 3: 1478-85.
66. Hardy JR, Noble T, Smith IE. Symptom relief with moderate dose chemotherapy (mitomycin-C, vinblastine and cisplatin) in advanced non-small cell lung cancer. Br J Cancer 1989; 60: 764-6.
67. Simes RJ. Risk-benefit relationship in cancer clinical trials: the ECOG experience in non-small cell lung cancer. J Clin Oncol 1985; 3: 462-72.
68. Aaronson NK, Ahmedzai S, Begman B et al. The European Organization for Research and Treatment of Cancer QLQ-C30. A quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993; 85: 365-76.
69. Cell DF, Tulsky DS., Gray G et al. The Functional Assessment of Cancer Therapy Scale: development of validation of the general measure. J Clin Oncol 1993; 11: 570-79.
70. Jaakimainen L, Goodwin PJ, Pater J et al. Counting the costs of chemotherapy in a National Cancer Institute of Canada randomized trial in non-small cell lung cancer. J Clin Oncol 1990; 8: 1301-9.
71. Smith TJ, Hillner BE, Neighbors DM et al. Economic evaluation of a randomized trial comparing vinorelbinc, vinorelbine plus cisplatin, and vindesine plus cisplatin for non-small-cell lung cancer. J Clin Oncol 1995; 13: 2166-73.
72. Evans WK, Le Chevalier T. The cost-effectiveness of navelbine alone or in combination with sisplatin in comparison to other chemotherapy regimens and best supportive care in stage IV non-small cell lung cancer. Eur J Cancer 1996; 32A: 2249-55.
73. Gralla RJ. Evaluating the cost and cost-effectiveness of new regimens for non-small cell lung cancer. Proc Am Soc Clin Oncol 1997: 14: 420a (abstract).